📰 Equinox Sciences News
Equinox Sciences News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Equinox Sciences. Real-time updates on events, politics, business and more.
February 3, 2024
Subgroup analyses underscore favorable clinical profile and durability of EYP-1901Presentations highlight previously reported positive Phase 2 DAVIO 2 topline results showing all primary and secondary...
January 17, 2024
WATERTOWN - EyePoint Pharmaceuticals, Inc. , a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced that...
December 4, 2023
WATERTOWN, Mass., Dec. 04, 2023 -- EyePoint Pharmaceuticals, Inc. , a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal...
October 31, 2023
WATERTOWN, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with retinal
September 11, 2023
- Interim analysis of masked data shows EYP-1901 is well tolerated with no reported drug-related ocular or systemic serious adverse events in Phase 2 PAVIA clinical trial in non-proliferative diabetic...
August 1, 2022
/PRNewswire/ -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the...
July 18, 2022
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
July 18, 2022
- Positive 12-Month Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD announced at ASRS 2022...
July 15, 2022
/PRNewswire/ -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the...
July 11, 2022
WATERTOWN, Mass., July 11, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and...